LSV Asset Management Increases Holdings in Charles River Laboratories International, Inc. $CRL

LSV Asset Management grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,773.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 297,800 shares of the medical research company’s stock after acquiring an additional 281,900 shares during the quarter. LSV Asset Management’s holdings in Charles River Laboratories International were worth $46,594,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Caprock Group LLC acquired a new position in Charles River Laboratories International in the third quarter valued at approximately $1,856,000. Rhumbline Advisers lifted its position in shares of Charles River Laboratories International by 1.5% during the 3rd quarter. Rhumbline Advisers now owns 96,569 shares of the medical research company’s stock worth $15,109,000 after buying an additional 1,427 shares during the last quarter. Madison Asset Management LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth approximately $1,935,000. Versor Investments LP acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $921,000. Finally, Midwest Trust Co grew its position in shares of Charles River Laboratories International by 3.5% in the 3rd quarter. Midwest Trust Co now owns 27,047 shares of the medical research company’s stock valued at $4,232,000 after buying an additional 906 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CRL. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Mizuho set a $215.00 target price on Charles River Laboratories International in a report on Friday, January 9th. Citigroup raised their price target on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Barclays boosted their price objective on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a research report on Monday, December 15th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $209.46.

Charles River Laboratories International Trading Up 1.5%

Shares of CRL stock opened at $161.15 on Friday. The business’s 50 day moving average is $203.27 and its two-hundred day moving average is $179.67. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $228.88. The company has a market capitalization of $7.93 billion, a P/E ratio of -103.30, a price-to-earnings-growth ratio of 4.76 and a beta of 1.63. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.